We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Progenics Pharmaceuticals announced additional positive data from a previously completed pivotal Phase III clinical trial of its investigational drug, methylnaltrexone (MNTX) for the treatment of opioid-induced constipation in patients with advanced medical illness.
Biopharmaceutical company Human Genome Sciences announced that GlaxoSmithKline (GSK) has exercised its option to help develop and commercialize a cancer treatment.
Genelabs Technologies announced positive results from a preliminary analysis of an open label clinical trial, which has met its primary objective of maintaining the bone mineral density (BMD) of women with systemic lupus erythematosus (SLE or lupus) receiving glucocorticoids.
NPS Pharmaceuticals announced that results from a Phase II clinical trial with the investigational drug teduglutide in subjects with short bowel syndrome (SBS), published in the September issue of the gastroenterology journal Gut, showed that daily subcutaneous injections of teduglutide achieved significant growth of the intestinal lining and improved dietary absorption of nutrients and fluids.
WEX Pharmaceuticals announced the results of the completed Phase IIa double-blind, placebo-controlled study of the efficacy and safety of tetrodotoxin in reducing withdrawal symptoms in methadone-maintained subjects.
Millennium Pharmaceuticals announced the initiation of a randomized, double-blind, placebo-controlled Phase II clinical trial of MLN1202 in patients at risk for atherosclerotic cardiovascular disease.
Sanofi-aventis has published results showing its breast cancer treatment Taxotere outperformed paclitaxel, which is marketed by Bristol-Myers Squibb under the brand name Taxol.